Business Wire

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials


Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.

This press release features multimedia. View the full release here:

CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.

Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.

CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.

Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.

CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.

Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.

Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

About Cerba HealthCare

Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.

Cerba HealthCare, enlightening health.

Additional information is available at

About Cerba Research

We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.​

We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.​

Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.

For more information visit


CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).

Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Press contacts:

Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10

CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Recover™ Appoints Anders Sjoblom as Chief Executive Officer28.9.2023 11:30:00 EEST | Press release

Recover™, the leading materials science company and scale producer of sustainable, high quality recycled cotton fiber and cotton fiber blends, today announced an expansion of its leadership team with the appointment of Anders Sjoblom as the company’s global chief executive officer, effective January 1, 2024, to drive its next stage of growth. Sjoblom is a seasoned executive that will join Recover from the H&M Group where he is global managing director for H&M lifestyle brands. Concurrent with Sjoblom’s appointment, fourth-generation family steward of Recover, Alfredo Ferre, will transition to a newly created role of chief product and innovation officer allowing his full focus on continued innovation and technical leadership at Recover inclusive of ensuring unparalleled product quality and transparency. The appointment of Sjoblom follows Recover’s recent appointment of Matthew Neville as the company’s first global chief commercial officer to build a customer-centric sales team and provi

Huawei joins the Sisvel Cellular IoT patent pool28.9.2023 11:03:00 EEST | Press release

Sisvel International S.A. (“Sisvel”) today announced that Huawei patents will now be available through its Cellular IoT technology patent pool after the company signed up to the programme as a licensor. The agreement means that more world class IP has been added to a pool which already includes patents from around 25 renowned innovators. At the same time, Sisvel has revealed new royalty rates for the Cellular IoT patent pool, including for devices with a lower selling price. The firm has also expanded its offering to new product verticals. Please see link for more details. The Sisvel Cellular IoT patent pool offers device manufacturers licences - on fair, reasonable, and non-discriminatory terms and conditions - to participants’ patent portfolios essential to the LTE-M and NB-IoT standards. “We are excited to welcome Huawei, a major contributor to the development of cellular IoT, as a member,” says Sisvel’s Cellular IoT programme manager, Sven Torringer. “LTE-M and NB-IoT technologies

Quectel Introduces EM060K-EA LTE-Advanced Cat 6 Module28.9.2023 11:00:00 EEST | Press release

Quectel Wireless Solutions, a global IoT solutions provider, is pleased to introduce the EM060K-EA LTE-Advanced Cat 6 module, offered for the EMEA, APAC and Brazil markets. The module, which is available in the M.2 form factor, measuring 30.0mm x 42.0mm x 2.3mm and powered by the Snapdragon® X12 LTE Modem from Qualcomm Technologies Inc, adopts 3GPP Release 12 technology and supports a theoretical peak date rate of 300 Mbps downlink and 50 Mbps uplink. The EM060K-EA can operate in extended temperature ranges from -25 °C to +75 °C, has a dedicated EMEA SKU and features power saving technology to ensure maximised deployment uptime. This press release features multimedia. View the full release here: Quectel introduces EM060K-EA LTE-Advanced Cat 6 module (Photo: Business Wire) Offering LTE-A and UMTS and HSPA+ coverage, the EM060K series has been designed for the global market and covers nearly all tier-one carriers worldwide. The mo

FRESOR's Big Breakthrough Shakes Up the European Vaping Industry28.9.2023 10:00:00 EEST | Press release

FRESOR, as the world's Leading Vaping Technology Platform, launched upgraded FRESOR NOVA technology and its latest product, FRESOR Slim at InterTabac 2023. This marks its first-ever launch in Germany and the third foray into the European market this year, following its successful debuts at Vaper Expo UK 2023 in Birmingham, UK, and Vapitaly 2023 in Italy in May. The exhibition achieved tremendous success, leaving a lasting impression on all attendees. This press release features multimedia. View the full release here: (Photo: Business Wire) "Where Flavor Meets Technology" On the opening day of the exhibition, September 14th, FRESOR hosted a spectacular product launch event at booth 3.F50, themed "Where Flavor Meets Technology." 1. Upgraded FRESOR NOVA technology During this event, FRESOR proudly unveiled its flagship offering – Upgraded FRESOR NOVA technology. This cutting-edge technology is specifically designed for small-capaci

AI Alignment Lab Achieves Major Milestone in Step Towards Agentic AI28.9.2023 08:00:00 EEST | Press release

Aligned AI, a leader in artificial intelligence (AI) research, has announced a groundbreaking AI advancement in misgeneralization, a critical challenge in the field of AI. It is the first to surpass a key benchmark called CoinRun by teaching an AI to “think” in human-like concepts. The technology underpinning the achievement opens the door to more precise, reliable, and controllable AI for a wide variety of real world applications. By teaching AI models to generalize in a manner more akin to agentic human cognition, Aligned AI’s innovation enables AI to correctly identify concepts across new situations and environments, reducing the need for prolonged production, testing, and retraining. Misgeneralization occurs when AI systems learn incorrect patterns and behaviors from their training data, and are not able to correctly adapt when presented with new information. This leads to unexpected, and often harmful, outcomes. Today’s foundation models suffer from varying degrees of misgeneraliz

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom